Vanda Pharmaceuticals | VNDA - Ebitda


Vanda Pharmaceuticals reported $-8.31M in EBITDA for its fiscal quarter ending in December of 2024.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -80.97M 93.7M Sep/2026
J&J USD 8.99B 721M Jun/2026
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
Ligand Pharmaceuticals USD 74.27M 88.56M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Moderna USD -1.26B 468M Mar/2026
Novartis USD 5.36B 45M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Sanofi EUR 5.79B 2.1B Sep/2026
Takeda JPY 369.75B 5.29B Sep/2026
Teva Pharmaceutical Industries USD 1.5B 1.02B Sep/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Veracyte USD 41.24M 2.72M Sep/2026